Literature DB >> 3124970

Association of meningococcal serogroups with the course of disease in the Netherlands, 1959-83.

L Spanjaard, P Bol, S de Marie, H C Zanen.   

Abstract

To study the association of meningococcal serogroups with the course of disease, we reviewed the case histories of 1221 patients. The meningococci from these patients constituted a sample from isolates collected and serogrouped systematically in the Netherlands since 1959. Of these 1221 isolates, 64% were serogroup B. The overall case fatality rate was 5.1%, and the rate was lowest for patients with serogroup A infections (2.3%) and highest for serogroup W135 (18%) (P < 0.01). The occurrence of septicaemia without meningitis (case fatality rate 15.3%) was similarly distributed among the serogroups (A, 4.0%; W135, 30%). Sequelae occurred in 7.9% of patients (loss of hearing, 3.2%) and were remarkably prevalent after disease due to minor serogroups (X and Y: 4 out of 12). In a log-linear analysis, both age and serogroup were significantly associated with case fatality rate and with the occurrence of septicaemia and sequelae. It is argued that these data are representative, despite the problems inherent in a retrospective investigation. The course and outcome of meningococcal disease appear to be related to the Neisseria meningitidis serogroup and to host factors.

Entities:  

Mesh:

Year:  1987        PMID: 3124970      PMCID: PMC2491086     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  22 in total

1.  Fatal meningococcal infections: the changing pathologic picture in the '60s.

Authors:  J M Hardman
Journal:  Mil Med       Date:  1968-12       Impact factor: 1.437

2.  Age-distribution of meningococcal disease as predictor of epidemics.

Authors:  L Spanjaard; P Bol; S de Marie; H C Zanen
Journal:  Lancet       Date:  1982-11-06       Impact factor: 79.321

3.  'The wheel within a wheel': meningococcal trends.

Authors:  G W Counts; R G Petersdorf
Journal:  JAMA       Date:  1980-11-14       Impact factor: 56.272

4.  Meningococcal disease in New York City, 1973 to 1978. Recognition of groups y and W-135 as frequent pathogens.

Authors:  E I Galaid; C E Cherubin; J S Marr; S Schaefler; J Barone; W Lee
Journal:  JAMA       Date:  1980-11-14       Impact factor: 56.272

5.  Association of meningococcal serotypes with the course of disease: serotypes 2a and 2b in the Netherlands, 1959-1981.

Authors:  L Spanjaard; P Bol; S de Marie; H C Zanen
Journal:  J Infect Dis       Date:  1987-02       Impact factor: 5.226

6.  Outcome of meningococcal group B meningitis.

Authors:  P D Moss
Journal:  Arch Dis Child       Date:  1982-08       Impact factor: 3.791

7.  Neisseria meningitidis serogroup W 135 disease in adults.

Authors:  R D Brandstetter; R J Blair; R B Roberts
Journal:  JAMA       Date:  1981-11-06       Impact factor: 56.272

Review 8.  Meningococcal disease: still with us.

Authors:  H Peltola
Journal:  Rev Infect Dis       Date:  1983 Jan-Feb

9.  Meningococcemia caused by serogroup W135. Association with hypogammaglobulinemia.

Authors:  I E Salit
Journal:  Arch Intern Med       Date:  1981-04

10.  Meningococcal disease in Scandinavia.

Authors:  H Peltola; K Jónsdóttir; A Lystad; C J Sievers; I Kallings
Journal:  Br Med J (Clin Res Ed)       Date:  1982-05-29
View more
  8 in total

1.  Comparison of commercial diagnostic tests for identification of serogroup antigens of Neisseria meningitidis.

Authors:  A van der Ende; I G Schuurman; C T Hopman; C A Fijen; J Dankert
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

2.  Variations in case fatality and fatality risk factors of meningococcal disease in Western Norway, 1985-2002.

Authors:  I Smith; A T Bjørnevik; I M B Augland; A Berstad; T Wentzel-Larsen; A Halstensen
Journal:  Epidemiol Infect       Date:  2006-02       Impact factor: 2.451

3.  High case-fatality rates of meningococcal disease in Western Norway caused by serogroup C strains belonging to both sequence type (ST)-32 and ST-11 complexes, 1985-2002.

Authors:  I Smith; D A Caugant; E A Høiby; T Wentzel-Larsen; A Halstensen
Journal:  Epidemiol Infect       Date:  2006-05-02       Impact factor: 2.451

4.  Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.

Authors:  Koen B Pouwels; Eelko Hak; Arie van der Ende; Hannah Christensen; Germie P J M van den Dobbelsteen; Maarten J Postma
Journal:  Hum Vaccin Immunother       Date:  2013-02-13       Impact factor: 3.452

5.  Fulminant meningococcal septic shock in a boy with combined inherited properdin and protein C deficiency.

Authors:  C A Fijen; B H Derkx; E J Kuijper; M Mannens; S R Poort; M Peters; M R Daha; J Dankert
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

6.  Patient and strain characteristics in relation to the outcome of meningococcal disease: a multivariate analysis.

Authors:  R J Scholten; H A Bijlmer; H A Valkenburg; J Dankert
Journal:  Epidemiol Infect       Date:  1994-02       Impact factor: 2.451

7.  Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands.

Authors:  Hiltsje Hepkema; Koen B Pouwels; Arie van der Ende; Tjalke A Westra; Maarten J Postma
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

8.  Improved survival of children with sepsis and purpura: effects of age, gender, and era.

Authors:  Martine Maat; Corinne M P Buysse; Marieke Emonts; Lodewijk Spanjaard; Koen F M Joosten; Ronald de Groot; Jan A Hazelzet
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.